Specific inclusion and exclusion criteria which allow entry into a clinical trial may be obtained by calling our Research Office (843.792.7262). All patients are required to have prior consultation to confirm their diagnosis and general health status prior to entering a treatment trial. Click here for general information about clinical trials. Studies Currently Enrolling:
A Phase 2, Double Blind, Placebo Controlled, Randomized, Parallel Group Multicenter Study of the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) as Monotherapy in Subjects with Parkinson’s Disease. (Kyowa Pharmaceutical, Inc). This three month study investigates the usefulness and safety of this novel drug in early PD before any other medication treatments have been used. The Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson’s Disease (Sponsor: Ovation Pharmaceuticals). The major goal of this project is to determine the safety and effectiveness of three different doses of melperone in the treatment of psychosis and hallucinations as part of Parkinson’s disease. Patients who benefit from treatment or who receive the placebo as part of the trial will get the opportunity to continue treatment as part of an open continuation study.
A Randomized, Double-blind, Crossover Study to Compare IPX 054 200 mg tablet BID to carbidopa-levodopa immediate release 100 mg tablet QID in subjects with Parkinson’s Disease (Sponsor: IMPAX Laboratories) The goal of this project is to compare IPX 054 (a new formulation of carbidopa/levodopa) 200 mg tablet twice a day to the standard carbidopa-levodopa immediate release 100 mg tablet four times a day. It is a brief crossover trial comparing two active treatments in a month’s time. For patients with focal dystonia: writer’s cramp or cervical dystonia (spasmodic torticollis). Functional Imaging of Motor Circuits in Dystonia (Sponsor: MCRPD, MUSC). We are investigating how brain circuits for movement are altered in dystonia by use of functional magnetic resonance imaging (fMRI). Dr. Vanessa Hinson is conducting these studies which are very noninvasive and require the ability to perform simple motor tasks during a special kind of MRI brain scan.
For patients with generalized dystonia: Deep Brain Stimulation in Dystonia: Humanitarian Device Exemption for Activa® Dystonia Therapy (Sponsor: Medtronic, Inc.) We are a regional center for investigation of the use of Deep Brain Stimulation as a treatment for generalized dystonia. Geographic Variation of Parkinson’s Disease in South Carolina: (Sponsors: The Fullerton Foundation, The Close to A Cure Foundation, United States Geological Survey (USGS), and The Murray Center for Research on Parkinson’s Disease and Related Disorders, MUSC) This project will attempt to create a model which predicts the development of PD. We know that this illness results from a complex interaction of environmental, biological, and genetic risk factors that an individual may carry. We are performing an in-depth interview of patients with PD, using a spouse, friend or family member as a control subject. We will combine their lifetime list of possible environmental and familial factors with data about SC soil and water that we obtain from a variety of other environmental sources. To participate you must have parkinsonism and have lived in one of the following SC zip codes for the five years before the first symptom of your illness:
29003, 29006,29018, 29038, 29039,29048, 29054, 29059, 29070, 29082, 29105, 29107, 29112, 29113, 29115, 29116, 29117, 29118, 29129, 29123, 29133, 29135, 29142, 29146, 29160, 29163, 29166, 29401, 29403, 29405, 29406, 29407, 29412, 29414, 29417, 29418, 29420, 29429, 29431, 29432, 29433, 29435, 29436, 29437, 29438, 29439, 29445, 29446, 29447, 29448, 29450, 29451, 29452, 29455, 29456, 29458, 29461,29464, 29466, 29470, 29471, 29472, 29474, 29475, 29477, 29481, 29483, 29484, 29485, 29487, 29488, 29493,29817, 29832, 29902, 29910, 29912, 29918, 29920, 29923, 29924, 29926, 29927, 29928, 29929, 29932, 29933, 29934, 29936, 29940, 29944, 29945 Studies Opening Soon: A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study in Subjects with Stably Treated Parkinson's Disease. (Sponsor: National Institute of Neurological Disorders and Stroke, Neuroprotection Exploratory Trials in Parkinson’s Disease: NINDS NET-PD) Enrollment is expected to open May, 2006. This trial will study the possible efficacy of a new drug to delay the progression of Parkinson’s disease in patients who are on stable treatment, in the early stages of the disease. Stay tuned for details. |
